â– PHYSIOLOGICAL CORE: Parathyroid Hormone (PTH) is synthesized and secreted by chief cells of the parathyroid gland, playing a key role in systemic calcium and phosphate homeostasis.
â– SENSING CHANNELS:
1. Calcium-Sensing Receptors (CaSR): G-protein-coupled CaSR are situated on the cell membranes of parathyroid chief cells.
2. High Calcium Inhibition: High extracellular ionized calcium binds to Gq-coupled CaSR, activating phospholipase C. This elevates intracellular calcium, which uniquely inhibits PTH secretion.
3. Low Calcium Release: Falling serum calcium reduces CaSR activation, releasing chief cells from inhibition and stimulating rapid PTH exocytosis.
4. Magnesium Regulation: Moderate hypomagnesemia stimulates PTH release. Severe hypomagnesemia impairs PTH secretion and causes end-organ resistance to PTH, leading to hypocalcemia.
â– PROGNOSTIC CRITERIA & TIMELINE:
Patient outcome scales correlate heavily with diagnostic staging at presentation, age, pre-existing comorbidities, and biological markers of cellular dividing rates.
â– SECONDARY PREVENTION METRICS:
Implementing long-term dietary adaptations, physical therapy, and compliance aids reduces the rate of recurring acute crises by more than half.
[HY-BOARD-1229]
🌟 Dynamic Clinical Key:
Familial Hypocalciuric Hypercalcemia (FHH) is caused by inactivating mutations in the CaSR gene. Parathyroid cells perceive a falsely low blood calcium level, requiring higher calcium concentrations to suppress PTH release. This results in mild asymptomatic hypercalcemia with low urinary calcium excretion. Regularly reassess clinical parameters to adjust long-term therapy. Patient education regarding warning signs and therapy adherence is the cornerstone of secondary prevention.